Proposed Framework for Policy Decision on RTS,S/AS01 Malaria Vaccine

Presentation to MPAC
10 Apr 2019
Results from RTS,S Phase 3 Trial, 2009-2014

- RTS,S/AS01 Phase 3 trial
  - 15,459 children, 11 sites, 7 African countries
  - 6-12 weeks or 5-17 months at first vaccination
- Children 5-17 months, 4 doses over 4 years
  - 39% reduction in clinical malaria
  - 29% reduction in severe malaria
  - **62% reduction severe malaria anaemia**
  - 29% reduction blood transfusions
- 4 doses provided optimal benefit;
  - 3 dose group had efficacy against clinical malaria, but not against severe malaria
- High impact
- Modeling: 1 life saved/200 vaccinated; highly cost-effective
Results from RTS,S Phase 3 Trial: Safety

- No vaccine-associated deaths
- Febrile convulsions, no sequellae
- Potential safety signals, with causality not established
  - In the 5-17 month age-category only
    - Imbalance in meningitis cases (10:1)
    - *Post hoc* analysis: numerically increased cerebral malaria cases (2:1, algorithmically derived)
  - In combined age-categories *post hoc* analysis: increased number of female deaths in those who received RTS,S vs. comparator vaccine 2:1

- Potential safety signals not observed in:
  - Pooled Phase II trials (n=2981)\(^1\)
  - Large ongoing Phase 3 trial in Mali and Burkina Faso (n=4000 vaccinated children; followed for >18 months)\(^2\)

2. Personal communication, Greenwood
Potential value of RTS,S/AS01: Immunization programmes tend to have higher reach than other health interventions
WHO position & pilot implementations

- Jul 2015: EMA positive scientific opinion under Article 58
- Oct 2015: SAGE/MPAC recommended **pilot implementation** to address outstanding questions:
  - **Feasibility** of reaching children with 4 doses
  - **Safety** in the context of routine use, emphasis on meningitis and cerebral malaria
  - **Impact** on mortality (including gender specific) and severe malaria
- Apr 2017: Kenya, Malawi, Ghana selected
- May 2018: NRAs authorized malaria vaccine for use in pilot areas
The 4 components of the MVIP

1. RTS,S/AS01 Implementation through EPI Programme
   - In selected areas

2. Pilot evaluation commissioned by WHO
   - Incl. sentinel hospitals surveillance; community-based mortality surveillance; 3 household surveys

3. Qualitative assessment (HUS) & economic analyses
   - commissioned by PATH

4. GSK Phase IV study
   - Safety, effectiveness and impact
   - Part of GSK’s EMA Risk Management Plan
Timeline of MVIP evidence generation and review

**Policy review**
- 2019: Regular updates to SAGE/MPAC
- 2020: Potential policy recommendation and policy refinement
- 2021: Potential policy recommendation and policy refinement
- 2022: Potential policy recommendation and policy refinement
- 2023: Policy refinement and recommendation

**Vaccine implementation**
- 2019: Start of vaccinations (Q1/Q2 2019)
- 2020: First 4th dose (Sep 2020 – Jan 2021)
- 2021: 30 months of routine vaccination (Sep 2021 – Jan 2022)
- 2022: Continued vaccination

**Safety data**
- Sentinel hospital surveillance
- Routine pharmacovigilance
- GSK Phase 4 study
- GSK baseline study
- Accumulating info
- GSK Phase 4 study on safety, effectiveness, and impact

**Impact data**
- Community-based mortality surveillance
- Sentinel hospital surveillance
- Impact on severe malaria
- Impact on mortality
- Accumulating info

**Feasibility data**
- Household surveys
- New vaccine post-introduction evaluation
- Health care utilization study
- Health economic assessments
- Administrative coverage data monitoring
  - Baseline
  - Coverage of dose 1-3
  - Coverage of dose 4
  - Qualitative longitudinal study
  - Costing of vaccine delivery
  - Budget impact analysis
Framework for Policy Decision for RTS,S/AS01

• Framework designed to guide how data collected through the MVIP will be used to inform a WHO policy recommendation on use of the RTS,S/AS01 malaria vaccine
Framework of Policy Decision (FPD) on RTS,S/AS01 Malaria Vaccine
Potential role in context of overall MVIP timelines and policy process

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>MVIP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Vaccination start

Evaluation complete

FPD

Framework to describe how MVIP data will be used for WHO policy recommendation*

Potential global policy recommendation & refinements

Implications

If recommended for broader use, decision making triggered on....

Funding

Vaccine implementation in 3 pilot countries

Vaccine introduction in other SSA countries

*For endorsement by SAGE and MPAC
## Working Group membership and representation

<table>
<thead>
<tr>
<th>Working group member</th>
<th>Representation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Fred Were</td>
<td>SAGE</td>
</tr>
<tr>
<td>2 Terry Nolan</td>
<td>SAGE member until Oct 2018</td>
</tr>
<tr>
<td>3 Gabriel Carrasquilla</td>
<td>MPAC</td>
</tr>
<tr>
<td>4 Umberto D’Alessandro</td>
<td>MPAC</td>
</tr>
<tr>
<td>5 Eusebio Macete</td>
<td>MVIP Programme Advisory Group (PAG)</td>
</tr>
<tr>
<td>6 Kim Mulholland</td>
<td>MVIP Programme Advisory Group</td>
</tr>
<tr>
<td>7 Peter Smith (Chair)</td>
<td>MVIP Programme Advisory Group</td>
</tr>
<tr>
<td>8 Quique Bassat</td>
<td>IVIR-AC</td>
</tr>
<tr>
<td>9 Melissa Penny</td>
<td>Modelers</td>
</tr>
</tbody>
</table>
Informing WG discussion: reviewed data and information to develop framework

- Prior policy decisions
- Timeframe from vaccine introduction (years)
- MAL 076, long term follow up study results
  - Clinical malaria: 4 doses: 24% (95% CI: 16, 31); 3 doses: 19% (95% CI: 11, 27)
  - Severe malaria: 4 doses: 37% (95% CI: 15, 53); 3 doses: 10% (95% CI: -18, 32)
  - Any rebound was time limited, few cases severe malaria after 4 years
  - No imbalance in safety signals or deaths during long term follow-up
- Updated results from mathematical models by Imperial College/SwissTPH
  - Suggest fourth dose provides minimal added benefit
  - Impact dependent on parasite prevalence, coverage with first 3 vaccine doses
  - Additional analysis of data from the Phase 3 trial (not shown)
- Timeline estimating when data on RTS,S/AS01 safety, feasibility, impact will be available based on assumptions used for statistical analysis
Expected **safety** data availability 24 months* after first pilot country begins vaccinations

1. **Meningitis (assume 0.4/1000/year):**
   - 80% power to rule out a 3-fold or greater increased rate of meningitis associated with introduction of RTSS vaccine
   - Phase 3 trial results: 8-fold increase

2. **Cerebral malaria (assume 2/1000/year):**
   - 90% power to rule out a 2-fold or greater increase in risk of cerebral malaria
   - Phase 3 trial: 2-fold increase

3. **Sex-specific mortality (assume mortality rate 8.5/1000/year):**
   - 90% power to exclude female:male mortality ratio being 1.2-fold higher in the RTSS arm than in the control arm
   - Phase 3 trial: 1.9-fold increase

*Timing may be updated if actual event rates deviate from assumptions*
Expected **impact** data availability 24 months* after first pilot country begins vaccinations

1. Severe malaria (assume incidence rate 2/1000/year):
   – >80% power to detect a 30% reduction in severe malaria by month 24 (data for all sentinel hospitals, all countries combined)
   – Phase 3 trial results: 29% reduction over 48 months with 4 dose schedule

2. Mortality (assume mortality rate 8.5/1000/year):
   – >80% power to detect a reduction in mortality by month 24 if the true reduction is 10%, (for all analyses, data for all countries combined)
   – Phase 3 trial results: no reduction/ not designed to measure impact on mortality

---

*Timing may be updated if actual event rates deviate from assumptions
Recommendations of the SAGE/MPAC Working Group (WG) on the Framework for Policy Decision on RTS,S/AS01

Umberto D’Alessandro
Working Group Member
Working Group approach – hierarchy of data

SAFETY
Reassuring safety data are considered of primary importance and pre-condition for a positive policy recommendation

IMPACT
Data trends assessed as consistent with a beneficial impact of the vaccine for:
- Impact on severe malaria: an acceptable surrogate indicator for impact on mortality
  or
- Impact on all-cause mortality

FEASIBILITY
Recommendation for broader use of RTS,S/AS01 need not be predicated on attaining high coverage including coverage of the 4th dose
Working Group approach – thought experiment

- Data on RTS,S/AS01, including Phase 3 trial results, were assessed by the EMA in 2015 and vaccine was given a “positive scientific opinion”

- Safety signals from Phase 3 trial were extensively discussed by SAGE/MPAC. It is possible that the SAGE/MPAC would have recommended the vaccine in 2016 had it not been for these signals

- WG took position that if data accumulate in MVIP to provide reassurance the safety signals observed in Phase 3 trial were likely due to chance, and impact on severe malaria or impact on mortality data trends were assessed as consistent with a beneficial impact of the vaccine-- it might be possible to make an initial recommendation for broader use before end of the MVIP

- Option would remain to refine the policy recommendation, if appropriate, when the full MVIP data set becomes available

- This strategy could accelerate the availability of a potentially life-saving vaccine
Step 1: Recommendation on use of RTS,S/AS01 beyond pilot countries could be made if:

i. concerns regarding safety signals observed in Phase 3 trial (meningitis, cerebral malaria and sex-specific mortality) are satisfactorily resolved, by demonstrating either the absence of a risk of an important size, or an assessment of a positive risk-benefit profile despite adverse event(s); and

ii. severe malaria trends are assessed as consistent with a beneficial impact; or

iii. mortality data trends are assessed as consistent with beneficial impact

Based on current assumptions related to vaccine introduction timings and expected rate of accumulating events, such data on safety and impact would be available approximately 24 months after RTS,S/AS01 introduction.*

*Timing may be updated if actual event rates deviate from assumptions
Step 2: Adjustments or refinements to policy recommendation for broader use of RTS,S/AS01 based on final MVIP data set, with particular focus on the value of fourth dose

Available approximately 50 months after start of vaccination in 3rd country

Recommendation 1: SAGE and MPAC should consider recommending a step-wise approach for review and policy decision on broader use of RTS,S/AS01 based on emerging pilot data
Proposed step-wise approach to policy recommendation

**Malaria Vaccine Implementation Programme**

- **Vaccination start** (first country)
- **24 months after start**
- **Evaluation complete** (46 months in last country)

**DATA**

- Safety data
- Impact data
- Feasibility data

**POLICY**

|------|------|------|------|------|------|------|

**Policy recommendation for broader use if and when:**

i. Concerns regarding safety signals satisfactorily resolved; and

ii. Severe malaria data trends assessed as *consistent with a beneficial impact* of the vaccine; or

iii. Mortality data trends assessed as *consistent with beneficial impact* of the vaccine

**Adjustments or refinements to policy recommendation if needed** based on the final MVIP data set

*Timing may be updated if actual event rates deviate from assumptions*
Rationale for step-wise approach

• A decision on the broader use of a potentially life-saving vaccine beyond the pilot countries should be made at earliest possible timepoint when robust evidence is available to ascertain a positive risk-benefit profile of the vaccine.

• Framework for Policy Decision seeks to reduce some uncertainty around the timing of a policy recommendation, which will facilitate advanced planning for potential outcomes, including:
  – An advanced signal to the manufacturer, that may be needed to maintain vaccine production and increase the likelihood of uninterrupted supply.
  – A trigger for financing mechanisms to be in place should there be a recommendation for broader use of RTS,S/AS01.
Recommendation 2: There is a need to resolve safety concerns on meningitis, cerebral malaria, and sex-specific mortality to establish the risk-benefit profile of the vaccine, as reassuring safety data are required for a policy recommendation.

• Mechanism to resolve safety concerns:
  – Data from sentinel hospitals in MVIP
  – GSK Phase 4 study (set up following EMA favourable assessment)
  – Routine pharmacovigilance reporting of AEFI and pre-specified AESI
  – All subject to ongoing review by DSMB

• Estimated data availability:
  – Assuming no true excess risk of meningitis, cerebral malaria or female mortality, relative risks of specified magnitude could be ruled out approximately 24 months after vaccine introduction

• Other considerations:
  – If any excess risks observed, risk-benefit assessments necessary
  – Benchmarking against other vaccines with known risks (e.g. rotavirus vaccine risk of intussusception) would be useful
Recommendation 3: The policy recommendation for broader use could be made in the absence of data showing vaccine impact on mortality. Impact on severe malaria is an acceptable surrogate indicator for impact on mortality, and could support a policy recommendation if assessed as consistent with a beneficial impact.

- WG recommendations on impact on severe malaria and mortality align with MPAC recommendations made in Oct 2018, based on MAL 076
  - Concern regarding a potential excess risk of severe malaria in long-term follow-up of children who miss 4th dose has been reduced
- Estimated data availability: Data on the impact on severe malaria may be available approximately 24 months after vaccine introduction
  - Unlikely that a 10% country-specific impact on mortality demonstrable before pilot evaluations end
- Policy precedence: SAGE has not required demonstration of mortality impact for other vaccines prior to making initial recommendation for vaccine use. Data on mortality impact have resulted in modifications of recommendations.
- Other considerations: Impact of vaccine on severe malaria would not necessarily be the same in programmatic implementation as in the Phase 3 trial
Recommendation 4: A policy recommendation for broader use of RTS,S/AS01 need not be predicated on attaining high coverage (including coverage of the fourth dose).

- MAL-076 long-term follow up data indicate
  - rebound in severe malaria among children who received only 3 doses of RTS,S/AS01 was time limited
  - absence of rebound after 4th dose

- **Policy precedence:**
  - Implementation data are rarely available at time of initial vaccine policy recommendation, rather findings from post-marketing studies are incorporated later

- **Target threshold for vaccine coverage (incl. 4th dose) should not be defined to inform a policy decision.**
  - Vaccine coverage attained, and methods used to increase coverage, can be used to guide future strategies for improved vaccine implementation
Recommendation 5: **Barring substantial adverse impact on coverage of other vaccines or malaria control interventions, effect of RTS,S/AS01 introduction on coverage of these interventions should not influence policy recommendation.** Rather these indicators should inform strategies for implementation, including areas to call attention or provide opportunities for improvement.

- RTS,S/AS01 is proposed as complementary to other malaria interventions
- RTS,S/AS01 immunization regimen provides new contacts for children in 2YOL*, providing opportunities to increase coverage of other childhood vaccines and enhance delivery of other malaria interventions
- MVIP includes interviews of parents and health workers to understand the obstacles and opportunities for vaccine delivery
- Reduction in health intervention uptake, coverage or use associated with vaccine introduction could be addressed with targeted action and/or messaging

*2YOL=second year of life
Recommendation 6: Cost-effectiveness estimates should be regularly refined, as data become available for increasingly precise calculations, and presented at appropriate time points.

- Cost-effectiveness of RTS,S/AS01 was assessed as favourable compared to that of several other vaccines
  - RTS,S/AS01 is expected to be highly cost-effective in moderate to high malaria transmission settings alongside other malaria interventions

- **Policy precedence**: Cost-effectiveness is rarely incorporated into an initial vaccine policy recommendation for broader use

- Need to validate and/or update existing modelled estimates on public health impact and cost-effectiveness

- Cost-effectiveness estimates for SAGE/MPAC should be refined as more data become available from MVIP
Recommendation 7: Expansion within MVIP countries should be synchronized with recommendation for broader use across sub-Saharan Africa.

- In MVIP, vaccine deployment for 30 months (minimum):
  - MVIP countries could decide to continue vaccinations, as any pause is detrimental to programme operations and community mobilization
  - Vaccination in comparison areas advised by the WHO Ethics Committee
- There should be regular SAGE/MPAC briefings on plans for vaccine expansion
- Provided there is sufficient vaccine supply, NRAs are in agreement, and a positive risk/benefit profile is maintained, vaccine should not be withheld from comparison areas until after MVIP end
- Important to address risk of vaccination interruption in advance, due to time required for decision making, financing, vaccine availability, and implementation planning
  - Creative mechanisms should be considered to ensure supply and funding are available
Recommendation 8: In the context of step-wise approach to policy recommendations, the pilots should continue through to completion of data collection to establish the public health value of the fourth dose, including assessment of the vaccine’s impact on mortality.

- The MVIP should continue to generate data through end of evaluation (expected to be 46 months in each country)
  - Regardless of whether an earlier policy recommendation is provided (barring a safety concern resulting in stopping MVIP)
- If it is found upon completion of the Programme that the 4th dose provides little incremental benefit, the initial recommendation could be modified (e.g. to a 3-dose regimen)
Recommendation 9: **Conflicting data among MVIP countries would require careful investigation into the reasons for differences.** Continue forward with plans for analysis even if data are delayed or not available in all countries.
Recommendation 10: Criteria are suggested that could result in WHO not making a recommendation for use of vaccine in routine immunization programmes or deferring a policy decision to a later time point.

• To *not make a recommendation* if:
  – there is a clear safety risk (e.g. an excess of meningitis among those vaccinated) assessed to be unfavourable in context of risk-benefit profile, or
  – there is something in the risk-benefit profile that could critically undermine the confidence and trust in national immunization programmes

• To *defer a decision* to the end of the pilot evaluations if:
  – there is significant uncertainty about safety issues (meningitis, cerebral malaria, sex-specific mortality), or
  – much less than expected impact on hospitalized malaria
Conclusion

• Value of Framework as future reference depends on joint support from SAGE/MPAC
  – SAGE endorsed the Framework on 3-Apr; SAGE chair and SAGE Working Group members invited to join MPAC session today
  – MPAC requested to consider formal endorsement of Framework in its closed session

• SAGE/MPAC endorsement of the proposed Framework would imply
  – Once data described for step 1 is available, SAGE/MPAC would be requested to consider a policy recommendation for broader use of RTS,S/AS01 in sub-Saharan Africa
  – Regular update on MVIP progress will continue to be provided
  – Regional and country consultation in lead up to policy decision
Thank you
Expert review: Treatment assignment *per* study period for all “Confirmed” cases of cerebral malaria (n=23)

<table>
<thead>
<tr>
<th>Study period (Month)</th>
<th>R3R+R3C</th>
<th>R3R</th>
<th>R3C</th>
<th>C3C</th>
</tr>
</thead>
<tbody>
<tr>
<td>M0-20</td>
<td>--</td>
<td>2</td>
<td>6</td>
<td>4</td>
</tr>
<tr>
<td>M21-SE</td>
<td>--</td>
<td>3</td>
<td>6</td>
<td>2</td>
</tr>
</tbody>
</table>

*23/340 (6.8%) cases where at least one expert felt that it was a case of cerebral malaria (i.e. the 18 cases where both experts agreed/assessed as “Confirmed” plus 5 cases where there was disagreement but at least one assessor felt that it was a case of cerebral malaria).*
Expert Review: Treatment assignment per study period for all “Possible” cases of cerebral malaria (i.e. n=37)

<table>
<thead>
<tr>
<th>Study period (Month)</th>
<th>R3R+R3C</th>
<th>R3R</th>
<th>R3C</th>
<th>C3C</th>
</tr>
</thead>
<tbody>
<tr>
<td>M0-20</td>
<td>--</td>
<td>3</td>
<td>10</td>
<td>7</td>
</tr>
<tr>
<td>M21-SE</td>
<td>--</td>
<td>7</td>
<td>8</td>
<td>2</td>
</tr>
</tbody>
</table>

37/340 (10.9%) cases where either both experts agreed that they were cases of cerebral malaria (n=18) or both experts were uncertain/could not rule-out whether it was a case of cerebral malaria or not (n=13) or both experts disagreed but at least one expert felt that it was a case of cerebral malaria or was uncertain/could not rule it out (n=6).
### Serious Adverse Events: Meningitis 5-17 Months Group

<table>
<thead>
<tr>
<th>5-17 month age group</th>
<th>4 dose schedule N=2976</th>
<th>3-dose schedule N=2972</th>
<th>Controls N=2974</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>%</td>
<td>n</td>
</tr>
<tr>
<td>At least one SAE</td>
<td>720</td>
<td>24.2</td>
<td>752</td>
</tr>
<tr>
<td>At least one SAE</td>
<td>673</td>
<td>22.6</td>
<td>704</td>
</tr>
<tr>
<td>excluding malaria</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatal SAE</td>
<td>61</td>
<td>2.0</td>
<td>51</td>
</tr>
<tr>
<td>At least one related SAE</td>
<td>8</td>
<td>0.3</td>
<td>4</td>
</tr>
<tr>
<td>Meningitis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(any pathogen)</td>
<td>11</td>
<td>0.4</td>
<td>10</td>
</tr>
</tbody>
</table>

Source: JTEG Background paper (Sept 2015)

Low number of meningitis cases in control arm of 5-17 month olds age-category
Models indicate RTS,S is cost-effectiveness

• At a hypothetical vaccine price of $5 a dose median incremental vaccine cost effectiveness ratio is
  – $87 (range $48-$244) per DALY averted
  – $25 ($16-$222) per clinical case averted.

• RTS,S compares favourably relative to global cost effectiveness estimates of several other vaccines.
## RTS,S schedule

WHO position: A 4-dose schedule is required, with the first dose given as soon as possible after 5 months of age, doses 2 and 3 given at monthly intervals, and the fourth dose given 15–18 months after the third dose.

**Example: Ghana vaccination schedule**

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Age</th>
<th>Birth</th>
<th>6 weeks</th>
<th>10 weeks</th>
<th>14 weeks</th>
<th>5 mo</th>
<th>6 mo</th>
<th>7 mo</th>
<th>9 mo</th>
<th>12 mo</th>
<th>18 mo</th>
<th>22 mo</th>
<th>24 mo</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCG</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OPV</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DPT-HepB-Hib (penta)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCV</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rota</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IPV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>MenA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>MR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>YF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>RTS,S Ghana</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RTS,S Kenya</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>RTS,S Malawi</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>VitA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>
## Programme Advisory Group members

<table>
<thead>
<tr>
<th>Name</th>
<th>Focus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nick Andrews</td>
<td>Statistics, vaccine safety, GACVS</td>
</tr>
<tr>
<td>Dominique A. Caugant</td>
<td>Meningitis, vaccine impact evaluation</td>
</tr>
<tr>
<td>Corine Karema</td>
<td>Malaria in Africa, programme implementation, impact evaluation</td>
</tr>
<tr>
<td>Eusebio Macete</td>
<td>Clinical trials of RTS,S and other malaria control interventions, child health</td>
</tr>
<tr>
<td>Kim Mulholland</td>
<td>Vaccine evaluation, child health, meningitis</td>
</tr>
<tr>
<td>Graham Brown</td>
<td>Malaria research, Immunology, vaccines, MPAC</td>
</tr>
<tr>
<td>Adelaide Eleanor Shearley</td>
<td>Immunization programme management, child health, IPAC</td>
</tr>
<tr>
<td>Peter Smith</td>
<td>Implementation research, epidemiology, statistics</td>
</tr>
<tr>
<td>Fredrick Were</td>
<td>Vaccine and immunization research, child health, SAGE</td>
</tr>
</tbody>
</table>
# DSMB members

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alex Dodoo</td>
<td>Pharmacovigilance, GACVS, Malaria</td>
</tr>
<tr>
<td>Cynthia Whitney</td>
<td>Epidemiology, Meningitis,</td>
</tr>
<tr>
<td>Esperança Severe</td>
<td>Pharmacovigilance, Regional PV systems</td>
</tr>
<tr>
<td>Kate O'Brien</td>
<td>Epidemiology, SAGE, Meningitis, Vaccine Safety</td>
</tr>
<tr>
<td>Charles Newton</td>
<td>Paediatric neurology, Epidemiology, Cerebral Malaria, Meningitis</td>
</tr>
<tr>
<td>Larry Moulton</td>
<td>Statistics, Epidemiology</td>
</tr>
<tr>
<td>Jane Achan</td>
<td>Epidemiology, Child health, Malaria</td>
</tr>
</tbody>
</table>
Status: Global, regional, country communications

- General information about the MVIP on the WHO website
- Brochure on the MVIP
- FAQ about the MVIP
- FAQ about the RTS,S/AS01 Phase 3 trial results

Global and country level

- Crisis communication plan, table top exercise
- Launch plans, media engagement, spokesperson training
- Country level engagement with policy makers, including parliamentarian, opinion leaders, religious and community leaders, medical community
- Information, Education and Communication materials and training materials
Informing WG discussion: reviewed data and information to develop framework

• Existing data and information
  – Results from Phase 3 trial
  – JTEG report, SAGE/MPAC recommendation and WHO position paper
  – Prior vaccine policy decisions: Rotavirus, pneumococcal conjugate, and dengue vaccines case studies
  – Prior malaria intervention policy decisions: Insecticide treated nets (ITN), Intermittent preventive treatment in infants (IPTi)/pregnancy (IPTp)
New data reviewed by the Working Group Mal 076, Long term follow-up

- Additional 3 years at 3/11 Phase 3 sites* (7 years total)
- Open label
- Data collection: mix of retrospective and prospective
- Overall vaccine efficacy during 7 year follow-up
  - Clinical malaria: 4 doses: 24% (95% CI: 16, 31); 3 doses: 19% (95% CI: 11, 27)
  - Severe malaria: 4 doses: 37% (95% CI: 15, 53); 3 doses: 10% (95% CI: -18, 32)
- No excess cases of severe malaria (rebound) in any group
  - Any rebound in severe malaria that may have occurred in 3-dose group was time-limited
  - No rebound after 4th dose
- Very few severe malaria cases after 4 years follow-up in any arm
- No imbalance in safety signals or deaths during long term follow-up

*Korogwe (Tanzania), Kombewa (Kenya), Nanoro (Burkina Faso)
Operational feasibility:
Expected new vaccine coverage & trajectory over time

MCV2 WHO/UNICEF estimated coverage* in Ghana, Kenya and Malawi, 2012-2017

*according to WHO/UNICEF coverage estimates, as of 15 July 2018